Journal Information

Statistics

Follow this link to access the full text of the article

Research letter
MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+
F. Barataa,
Corresponding author
fjssbarata@gmail.com

Corresponding author.
, H. Queirogab, E. Teixeirac, M.T. Almodovard, B. Parentee, M. Soaresf
a Assistente Hospitalar Graduado de Pneumologia, Centro Hospitalar e Universitário de Coimbra, Portugal
b Professor da Faculdade de Medicina do Porto, Assistente Hospitalar Sénior, Centro Hospitalar de S João, Portugal
c Assistente Hospitalar Graduada de Pneumologia, Centro Hospitalar Lisboa Norte, Portugal
d Assistente Hospitalar Graduada Pneumologia, Instituto Português Oncologia Lisboa Francisco Gentil, Rua Professor Lima, Basto, 1089 Lisboa, Portugal
e Assistente Hospitalar Sénior de Pneumologia, Centro Hospitalar Gaia/Espinho, Portugal
f Assistente Hospitalar de Oncologia Médica, IPOPORTOFG, Portugal
Read
1187
Times
was read the article
676
Total PDF
511
Total HTML
Share statistics
Article information
ISSN: 21735115
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 December 18 31 49
2024 November 41 49 90
2024 October 40 29 69
2024 September 32 26 58
2024 August 38 40 78
2024 July 32 36 68
2024 June 29 25 54
2024 May 30 51 81
2024 April 27 38 65
2024 March 22 35 57
2024 February 30 32 62
2024 January 24 33 57
2023 December 17 38 55
2023 November 21 34 55
2023 October 24 45 69
2023 September 19 29 48
2023 August 9 19 28
2023 July 20 28 48
2023 June 13 27 40
2023 May 16 22 38
2023 April 9 9 18
Show all

Follow this link to access the full text of the article

Pulmonology

Are you a health professional able to prescribe or dispense drugs?